	US 12,065,472 B2
	Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
Roman Fischer, Nuremberg (DE); Roland Kontermann, Nuremberg (DE); Klaus Pfizenmaier, Tiefenbronn (DE); and Martin Siegemund, Stuttgart (DE)
Assigned to UNIVERSITÄT STUTTGART, Stuttgart (DE)
Filed by UNIVERSITÄT STUTTGART, Stuttgart (DE)
Filed on Sep. 2, 2021, as Appl. No. 17/465,186.
Application 17/465,186 is a division of application No. 16/500,849, granted, now 11,142,558, previously published as PCT/EP2018/058786, filed on Apr. 5, 2018.
Claims priority of application No. 17165279 (EP), filed on Apr. 6, 2017.
Prior Publication US 2021/0395323 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/525 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/525 (2013.01) [A61K 38/00 (2013.01); C07K 2319/30 (2013.01)]

21 Claims

1. A tumour necrosis factor receptor (TNFR) binding protein complex comprising 12 or more protein ligands (PLs) that specifically bind to the extracellular part of the same TNFR, -wherein each PL comprises a TNF homology domain of a TNF-ligand family member protein (THD), -and each THD is, independently of each other, selected from the group consisting of TNF, a TNF-related apoptosis inducing ligand (TRAIL or TNFSF10, tumor necrosis factor superfamily member 10), CD40L (TNFSF5), CD27L (TNFSF7), CD30L (TNFSF8), FasL (TNFSF6), 4-1BBL (TNFSF9), OX40L (TNFSF4), EDA; LTA (TNFSF1), LTB (TNFSF3), CD153 (TNFSF8), RANKL (TNFSF11), TWEAK (TNFSF12), APRIL (TNFSF13), BAFF (TNFSF13B), LIGHT (TNFSF14), VEGI (TNFSF15), and GITRL (TNFSF18).